Cite
HARVARD Citation
Michel, P. et al. (2018). Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). Digestive and liver disease. 50 (3), pp. 305-307. [Online].